Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/09/21 16:21:21」(JST)

wiki en

Ciclesonide is a glucocorticoid used to treat asthma and allergic rhinitis. It is marketed under the brand name Alvesco for asthma and Omnaris/Omniair for hay fever in the US and Canada. Phase 3 trials for the hay fever indication outside the US are ongoing.^[1] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006.^[2] Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.^[3]

References[edit source | edit]

^ "OMNARIS/OMNAIR". Products. Nycomed International Management GmbH. 2009. Retrieved 2009-07-30. ^{[dead link]}
^ "FDA NEWS RELEASE. FDA Approves New Treatment for Allergies.". Food and Drug Administration. 2006-10-23. Retrieved 2009-07-30.
^ Mutch, E; Nave R, McCracken N, Zech K, Williams FM (May 2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue.". Biochem Pharmacol. (England: Elsevier Science) 73 (10): 1657–1664. doi:10.1016/j.bcp.2007.01.031. ISSN 0006-2952. PMID 17331475. Retrieved 2007-07-30.

Rossi S (Ed.) (2006). Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook. ISBN 0-9757919-2-3

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 吸入ステロイドの主な副作用 major side effects of inhaled glucocorticoids
2. 慢性鼻副鼻腔炎：マネージメント chronic rhinosinusitis management
3. 好酸球性食道炎の治療 treatment of eosinophilic esophagitis
4. 12歳未満の小児における慢性喘息：持続性喘息の治療およびコントロール薬 asthma in children younger than 12 years treatment of persistent asthma with controller medications
5. アレルギー性鼻炎の薬物療法 pharmacotherapy of allergic rhinitis

English Journal

Differences in Adherence to Common Inhaled Medications in COPD.

Huurne KK1, Movig K, van der Valk P, van der Palen J, Brusse-Keizer M.
COPD.COPD.2015 Aug 19:1-6. [Epub ahead of print]
OBJECTIVE: To study differences in adherence to common inhaled medications in COPD.METHODS: Adherence of 795 patients was recorded from pharmacy records over 3 years in the COMIC cohort. It was expressed as percentage and deemed good at ≥75-≤125%, sub-optimal ≥50-<75%, and poor <50% (un
PMID 25775100

Formoterol synergy with des-ciclesonide inhibits IL-4 expression in IgE/antigen-induced mast cells by inhibiting JNK activation.

Sun YH1, Ge LT2, Jiang JX1, Shen HJ1, Jia YL1, Dong XW1, Sun Y2, Xie QM3.
European journal of pharmacology.Eur J Pharmacol.2015 Aug 15;761:161-7. doi: 10.1016/j.ejphar.2015.05.008. Epub 2015 May 19.
Inhaled corticosteroid (ICS) therapy in combination with long-acting β-adrenergic agonists (LABA) is the most important treatment for allergic asthma, although the mechanism still remains unclear. However, mast cells play a central role in the pathogenesis of asthma. In this study, we explored the
PMID 26003274

Evidence of hypothalamic-pituitary-adrenal axis suppression during moderate-to-high-dose inhaled corticosteroid use.

Cavkaytar O1, Vuralli D, Arik Yilmaz E, Buyuktiryaki B, Soyer O, Sahiner UM, Kandemir N, Sekerel BE.
European journal of pediatrics.Eur J Pediatr.2015 Aug 9. [Epub ahead of print]
The possible risk of adverse effects due to regular use of inhaled corticosteroids (ICS) is a real concern. Our aim was to describe the factors that have an impact on hypothalamic-pituitary-adrenal axis suppression (HPA-AS) in children and adolescents taking ICS regularly. The HPA axis status of pat
PMID 26255048

Japanese Journal

気管支喘息におけるシクレソニド(HFA-CIC)の末梢気道病変に対する治療効果の検討

加藤茂樹,内田善仁
川崎医学会誌 37(1), 15-18, 2011
NAID 110008594176

血清IgE低値でアレルゲンが明瞭でない重症喘息にオマリズマブが奏効した1例

杉野安輝,三田亮,高木康之,加藤誠章,大田亜希子,奥村隼也,長井秀明
アレルギー 59(11), 1572-1579, 2010-11-30
症例は49歳女性.高用量吸入ステロイド(フルチカゾン1000μg/日+シクレソニド800μg/日),サルメテロール吸入(100μg/日),ベタメサゾン内服(1mg/日)を中心とする多剤併用療法にても喘息コントロールが得られない重症難治性喘息であった.血清総IgE値は9(IU/mL)と低値で,明らかな通年性アレルゲンも認められなかったが,患者同意のもと2009年8月からオマリズマブ150mgを投与し …
NAID 110007989019

「シクレソニド」

Ciclesonide
Systematic (IUPAC) name
	2-[(1S, 2S, 4R, 8S, 9S,11S, 12S, 13R)-6-cyclohexyl-11-hydroxy-9, 13-dimethyl-16-oxo-5, 7-dioxapentacyclo [10.8.0.02,9.04, 8.013,18] icosa-14, 17-dien-8-yl]- 2-oxoethyl 2-methylpropanoate
Clinical data
AHFS/Drugs.com	monograph
MedlinePlus	a607008
Pregnancy cat.	B3 (AU) C (US)
Legal status	Prescription Only (S4) (AU) POM (UK) ℞-only (US)
Routes	nasal inhalation
Identifiers
CAS number	141845-82-1
ATC code	R01AD13 R03BA08
PubChem	CID 6918155
DrugBank	DB01410
ChemSpider	5293368
UNII	S59502J185
KEGG	D01703
ChEMBL	CHEMBL1201164
Synonyms	(11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione
Chemical data
Formula	C32H44O7
Mol. mass	540.688 g/mol
	SMILES O=C(OCC(=O)[C@]25O[C@@H](O[C@@H]5C[C@H]1[C@H]4[C@H]([C@@H](O)C[C@@]12C)[C@]/3(/C=C\C(=O)\C=C\3CC4)C)C6CCCCC6)C(C)C;
	InChI InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1 ; Key:LUKZNWIVRBCLON-GXOBDPJESA-N ;
(what is this?) (verify);

　　[★]

英: ciclesonide
商: オルベスコ

[1] "OMNARIS/OMNAIR". Products. Nycomed International Management GmbH. 2009. Retrieved 2009-07-30. ^{[dead link]}

[2] "FDA NEWS RELEASE. FDA Approves New Treatment for Allergies.". Food and Drug Administration. 2006-10-23. Retrieved 2009-07-30.

[mutch2007-3] Mutch, E; Nave R, McCracken N, Zech K, Williams FM (May 2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue.". Biochem Pharmacol. (England: Elsevier Science) 73 (10): 1657–1664. doi:10.1016/j.bcp.2007.01.031. ISSN 0006-2952. PMID 17331475. Retrieved 2007-07-30.

匿名

検索

案内

案内

ciclesonide